An announcement from Voyager Therapeutics (VYGR) is now available.
Voyager Therapeutics has appointed Nathan Jorgensen, a seasoned professional with a rich background in both the financial and biotech sectors, as their new Chief Financial Officer. Jorgensen, with his impressive credentials including a Ph.D. in neuroscience and an M.B.A., is set to take on his new role by July 2024. His diverse experience ranges from serving as CFO of Vor Biopharma to managing healthcare investments for the Qatar Investment Authority. Jorgensen’s compensation includes a substantial base salary, performance-based bonuses, and equity awards, aligning his interests with the company’s long-term success. This strategic hire points to Voyager’s commitment to strengthening its leadership and financial strategies as it progresses in the competitive biotech industry.
Find detailed analytics on VYGR stock on TipRanks’ Stock Analysis page.
